摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(8CI,9CI)-噻唑并[3,2-a]苯并咪唑 | 247-83-6

中文名称
(8CI,9CI)-噻唑并[3,2-a]苯并咪唑
中文别名
——
英文名称
thiazolo[3,2-a]benzoimidazole
英文别名
benzo[4,5]imidazo[2,1-b]thiazole;benzimidazolo[2,1-b]thiazole;thiazolo[3,2-a]benzimidazole;benzo[4,5]imidazo[2,1-b]thiazole;Thiazolo<3,2-a>benzimidazol;Thiazolo<3.2-a>benzimidazol;[1,3]Thiazolo[3,2-a]benzimidazole
(8CI,9CI)-噻唑并[3,2-a]苯并咪唑化学式
CAS
247-83-6
化学式
C9H6N2S
mdl
MFCD00524773
分子量
174.226
InChiKey
IHCQWURUZRYCIU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    12
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    45.5
  • 氢给体数:
    0
  • 氢受体数:
    2

安全信息

  • 海关编码:
    2934100090

SDS

SDS:ae55a9cdebfe8cde7ca95485a0309488
查看

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] HETEROTRICYCLYL 6-ALKYLIDENE-PENEMS AS BetaEpsilonTauAlpha-LACTAMASE INHIBITORS<br/>[FR] DERIVES D'HETEROTRICYCLYL 6-ALKYLIDENE-PENEMES EN TANT QU'INHIBITEURS DE BETA-LACTAMASE
    申请人:WYETH CORP
    公开号:WO2003093280A1
    公开(公告)日:2003-11-13
    The present invention provides a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
    本发明提供了一种I式化合物,药物组合物以及其用于治疗患有细菌感染或疾病的患者的用途。
  • PROCESS TO PREPARE NEW SUBSITUTED 1H-BENZO[d]IMIDAZOL-2(3H)-ONES, NEW INTERMEDIATES AND THEIR USE AS BACE 1 INHIBITORS
    申请人:Roussel Christian
    公开号:US20100120880A1
    公开(公告)日:2010-05-13
    The invention relates to a new process leading to new substituted 1H-benzo[d]imidazol-2(3H)-ones of formula III and III′, to pharmaceutical compositions comprising them and to their use as therapeutic agents, particularly as BACE 1 inhibitors in the treatment of Alzheimer disease.
    这项发明涉及一种新的过程,导致新的取代的1H-苯并[d]咪唑-2(3H)-酮,其化学式为III和III′,以及包含它们的药物组合物,以及它们作为治疗剂的用途,特别是作为治疗阿尔茨海默病的BACE 1抑制剂。
  • Tricyclic 6-alkylidene-penem beta-lactamase inhibitors and beta-lactam antibiotic combination: a broad spectrum antibiotic
    申请人:Mansour S. Tarek
    公开号:US20070027130A1
    公开(公告)日:2007-02-01
    The present invention provides a β-lactam antibiotic such as cefepime and a compound of formula I, pharmaceutical compositions and the use thereof for the treatment of bacterial infection or disease in a patient in need thereof.
    本发明提供了β-内酰胺类抗生素,如头孢吡肟以及化合物I的药物组合物,以及其用于治疗患有细菌感染或疾病的患者的用途。
  • Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors
    申请人:Mansour Suhayl Tarek
    公开号:US20060276446A1
    公开(公告)日:2006-12-07
    This invention relates to certain tricyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. β-Lactamases hydrolyze β-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with β-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of formula I which are useful for treatment of bacterial infections having class-D enzymes associated therewith: wherein: One of A and B denotes hydrogen and the other an optionally substituted fused tricyclic heteroaryl group; and X is S or O.
    这项发明涉及某些三环6-烷基亚胺基青霉素,其作为类D酶的抑制剂。β-内酰胺酶水解β-内酰胺类抗生素,因此是细菌抗药性的主要原因。本发明的化合物与β-内酰胺类抗生素结合时,将提供一种有效治疗危及生命的细菌感染的方法。根据本发明,提供了以下公式I的化合物,其用于治疗与类D酶相关的细菌感染:其中:A和B中的一个表示氢,另一个表示可选择取代的融合三环杂芳基团;X为S或O。
  • TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE
    申请人:DUBOIS Laurent
    公开号:US20090042873A1
    公开(公告)日:2009-02-12
    The invention concerns tricyclic N-heteroarylcarboxamide derivatives containing a benzimidazole unit of general formula (I): Wherein A, P, Y, R 1 , R 2 and R 3 are as defined herein. The invention also concerns a method of preparing the compounds and their therapeutic use.
    这项发明涉及含有通式(I)中苯并咪唑单元的三环N-杂环酰胺衍生物,其中A、P、Y、R1、R2和R3如本文所定义。该发明还涉及制备这些化合物的方法及它们的治疗用途。
查看更多